Cesca Therapeutics Inc (NASDAQ:KOOL) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokers have set a 12 month consensus target price of $6.50 for the company and are expecting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also given Cesca Therapeutics an industry rank of 83 out of 256 based on the ratings given to its competitors.
KOOL has been the topic of a number of recent analyst reports. ValuEngine raised shares of Cesca Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd. HC Wainwright reissued a “buy” rating and issued a $6.50 price target (up previously from $1.00) on shares of Cesca Therapeutics in a research report on Wednesday.
Cesca Therapeutics (NASDAQ:KOOL) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.13. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. The company had revenue of $4.31 million for the quarter, compared to analyst estimates of $3.40 million. On average, analysts forecast that Cesca Therapeutics will post -2 EPS for the current year.
About Cesca Therapeutics
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
Further Reading: What is Elliott Wave theory?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.